Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
100%
Follicular Lymphoma
66%
Overall Survival
61%
Lymphoma
50%
Event-free Survival
39%
Hazard Ratio
38%
Newly Diagnosed
35%
Lymphoma Patients
33%
Confidence Interval
32%
Immunochemotherapy
26%
Ovarian Cancer
25%
International Prognostic Index
25%
Rituximab
22%
Progression-free Survival
21%
Non-Hodgkin Lymphoma
21%
Molecular Epidemiology
18%
R-CHOP
18%
Mantle Cell Lymphoma
17%
High Risk
17%
Clinical Outcomes
16%
Mayo Clinic
15%
Clinical Trials
14%
Chemotherapy
12%
Cancer Treatment
12%
Relapsed or Refractory
12%
Rituximab Era
11%
Prognostic Score
11%
Tumor
11%
Prognostic Factors
11%
North Central
10%
Doxorubicin
10%
Working Diagnosis
10%
Epidemiology
10%
Quality of Life
10%
Phase II Trial
10%
B-cell Lymphoma 2 (Bcl-2)
10%
Survival Outcomes
9%
Treatment Group
9%
Prednisone
9%
Chronic Lymphocytic Leukemia
8%
Cyclophosphamide
8%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
8%
B Cells
8%
Free Light Chains
8%
Single nucleotide Polymorphism
8%
Serum Cytokines
8%
Patient-derived Xenograft
8%
Ovarian Cancer Patients
8%
Lymphoma Subtype
7%
Peripheral T-cell Lymphoma
7%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
77%
Overall Survival
62%
Follicular Lymphoma
57%
Diseases
37%
Ovarian Cancer
35%
Event Free Survival
34%
Non-Hodgkin Lymphoma
28%
Rituximab
26%
Hazard Ratio
26%
Clinical Trial
21%
Neoplasm
20%
Mantle Cell Lymphoma
19%
Molecular Epidemiology
19%
B Cell
18%
Krukenberg Tumor
17%
Progression Free Survival
16%
International Prognostic Index
14%
Cohort Analysis
13%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
13%
Prognostic Factor
13%
Biological Marker
12%
B-Cell Lymphoma
11%
T Cell
11%
Cohort Effect
11%
Hodgkin's Lymphoma
10%
Light Chain
10%
Xenograft
10%
Malignant Neoplasm
9%
Doxorubicin
8%
Quality of Life
7%
Germinal Center
7%
Cyclophosphamide
7%
Vincristine
7%
Positron Emission Tomography
7%
Hematologic Malignancy
7%
MALT Lymphoma
7%
Lymphoma Cell
6%
Prednisone
6%
Chemoimmunotherapy
6%
Cancer Therapy
6%
Anthracycline
6%
Aggressive Lymphoma
6%
Drug Megadose
5%
Cytokine
5%
Immunohistochemistry
5%
B-Cell Chronic Lymphocytic Leukemia
5%
Single Nucleotide Polymorphism
5%
Regulatory T Cell
5%
Oncology
5%
Cumulative Incidence
5%